Abstract
RNA interference (RNAi) is a mechanism in which double-stranded (ds) RNA acts as a guide to sequence-specifically suppress gene expression. To achieve targeted knock-downs of gene function in mammalian cells, in vitro synthesised small interfering RNAs (siRNAs) can be introduced transiently into cells or, for more stable suppression by RNAi, various vector strategies can be employed to achieve prolonged in vivo synthesis of targeting RNA sequences. RNAi, beyond being a powerful experimental tool, has been widely promoted as a future gene-targeted therapeutic strategy of exquisite specificity. In the context of cancer, in which mutation, over-expression and de-novo acquisition of tumour-promoting genes are of central importance to the pathology, multiple molecular targets have been proposed for RNAi-based therapies. In this review, we will summarise what is known about the biology of RNAi in mammalian cells, outline the various expression and delivery strategies that have been developed, and discuss the features of possible therapeutic gene targets. We will also highlight the present technical limitations of RNAi that will need to be addressed if it is to be developed therapeutically, including the important issues of effective delivery and the potential for development of tumour resistance.
Keywords: cancer, rnai, rna interference, therapy, tumor
Current Cancer Therapy Reviews
Title: RNA Interference: A New Targeted Tumour Therapy?
Volume: 1 Issue: 1
Author(s): Jane M.E. Withey and Mark R. Crompton
Affiliation:
Keywords: cancer, rnai, rna interference, therapy, tumor
Abstract: RNA interference (RNAi) is a mechanism in which double-stranded (ds) RNA acts as a guide to sequence-specifically suppress gene expression. To achieve targeted knock-downs of gene function in mammalian cells, in vitro synthesised small interfering RNAs (siRNAs) can be introduced transiently into cells or, for more stable suppression by RNAi, various vector strategies can be employed to achieve prolonged in vivo synthesis of targeting RNA sequences. RNAi, beyond being a powerful experimental tool, has been widely promoted as a future gene-targeted therapeutic strategy of exquisite specificity. In the context of cancer, in which mutation, over-expression and de-novo acquisition of tumour-promoting genes are of central importance to the pathology, multiple molecular targets have been proposed for RNAi-based therapies. In this review, we will summarise what is known about the biology of RNAi in mammalian cells, outline the various expression and delivery strategies that have been developed, and discuss the features of possible therapeutic gene targets. We will also highlight the present technical limitations of RNAi that will need to be addressed if it is to be developed therapeutically, including the important issues of effective delivery and the potential for development of tumour resistance.
Export Options
About this article
Cite this article as:
Withey M.E. Jane and Crompton R. Mark, RNA Interference: A New Targeted Tumour Therapy?, Current Cancer Therapy Reviews 2005; 1 (1) . https://dx.doi.org/10.2174/1573394052952447
DOI https://dx.doi.org/10.2174/1573394052952447 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Surface Plasmon Resonance Imaging Sensor for Cathepsin Determination Based on Immobilized Cystatin
Protein & Peptide Letters Targeting EZH2 for Cancer Therapy: Progress and Perspective
Current Protein & Peptide Science Dual Topoisomerase I / II Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization
Current Pharmaceutical Design The Molecular Machinery Regulating Apoptosis Signal Transduction and its Implication in Human Physiology and Pathophysiologies
Current Molecular Medicine Mechanism-based Combinations with Pim Kinase Inhibitors in Cancer Treatments
Current Pharmaceutical Design Histone Deacetylase Inhibitors: Recent Insights from Basic to Clinical Knowledge & Patenting of Anti-Cancer Actions
Recent Patents on Anti-Cancer Drug Discovery Multifunctional Anti-Cancer Nano-Platforms are Moving to Clinical Trials
Current Drug Metabolism Characterization of Cancer Stem Cells and Primary Cilia in Medulloblastoma
CNS & Neurological Disorders - Drug Targets Angiogenesis and Angiogenesis Inhibitors: a New Potential Anticancer Therapeutic Strategy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Edelfosine in Membrane Environment - the Langmuir Monolayer Studies
Anti-Cancer Agents in Medicinal Chemistry Regulation of Arylamine N-Acetyltransferases
Current Drug Metabolism Emerging Breast Cancer Biomarkers
Current Cancer Therapy Reviews Apoptosis Induction by Erucylphosphohomocholine via the 18 kDa Mitochondrial Translocator Protein: Implications for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry A New Synthetic Spiroketal: Studies on Antitumor Activity on Murine Melanoma Model In Vivo and Mechanism of Action In Vitro
Anti-Cancer Agents in Medicinal Chemistry Does Cyclic Dependent Kinase 5 Play a Significant Role in Determination of Stroke Outcome? Possible Therapeutic Implications
Central Nervous System Agents in Medicinal Chemistry Histone Lysine-Specific Methyltransferases and Demethylases in Carcinogenesis: New Targets for Cancer Therapy and Prevention
Current Cancer Drug Targets Never Sleep with Baby? Or Keep Me Close But Keep Me Safe: Eliminating Inappropriate “Safe Infant Sleep” Rhetoric in the United States
Current Pediatric Reviews Epigenetic Alterations of the Wnt/β -Catenin Pathway in Human Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Current View on the Mechanism of Action of Perifosine in Cancer
Anti-Cancer Agents in Medicinal Chemistry